Can l-arginine improve myocardial protection during cardioplegic arrest? Results of a phase I pilot study

Background. l-Arginine appears to improve myocardial protection during cardioplegic arrest in animal models. Methods. To study the clinical effect and safety of l-arginine in humans, a phase I pilot study was performed with 50 patients who underwent coronary artery bypass grafting. We randomly assig...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Annals of thoracic surgery 1998-07, Vol.66 (1), p.108-112
Hauptverfasser: Carrier, Michel, Pellerin, Michel, Pagé, Pierre L, Searle, Norman R, Martineau, Raymond, Caron, Claire, Solymoss, B.Charles, Pelletier, L.Conrad
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background. l-Arginine appears to improve myocardial protection during cardioplegic arrest in animal models. Methods. To study the clinical effect and safety of l-arginine in humans, a phase I pilot study was performed with 50 patients who underwent coronary artery bypass grafting. We randomly assigned half to a treatment group, which received 1 g of l-arginine administered during the first 30 minutes of cardioplegic arrest induced by either warm or cold blood cardioplegia, and half to a control group, which did not receive l-arginine supplementation. Results. Age, sex, and preoperative clinical status were similar in both groups. Seventeen patients of each group were administered intermittent warm antegrade blood cardioplegia, whereas the solution needed to be cooled to obtain complete standstill of the remaining eight hearts in each group. An internal thoracic artery graft to the left anterior descending coronary artery was performed in all patients. There was no death and no myocardial infarction in the treatment group, but there were one death and two infarctions in the control group. The amount of serial release of troponin I during the first 72 hours after the operation was similar between the l-arginine group and the control group ( p > 0.05). Peak serum troponin levels averaged 4.9 ± 1.0 μg/L in the arginine group and 3.9 ± 1.0 μg/L in the control group ( p > 0.05). A multivariate analysis of variance showed no effect of l-arginine ( p > 0.05) but a significant effect of the temperature of the cardioplegic solution on the release of troponin I ( p < 0.05). Serum troponin I levels averaged 2.2 ± 0.4 μg/L, 4.5 ± 0.4 μg/L, and 6.9 ± 0.4 μg/L in the patients with cold cardioplegia and 1.4 ± 0.3 μg/L, 2.4 ± 0.3 μg/L, and 3.3 ± 0.3 μg/L in the patients with warm cardioplegia 1, 2, and 6 hours, respectively, postoperatively. Conclusions. The administration of 1 g of l-arginine during the first 30 minutes of blood cardioplegic arrest did not result in a decrease in the postoperative release of cardiac enzyme; however, cold cardioplegic arrest significantly increased the release of cardiac troponin I postoperatively. There was no significant side effect related to the addition of l-arginine to the cardioplegic solution.
ISSN:0003-4975
1552-6259
DOI:10.1016/S0003-4975(98)00321-X